The Experimental Research of BTJF Medicated Serum Inhibiting on Growth of BXPC-3 Pancreatic Cancer Cell
Hu Bo1,Cheng Xin Sheng2,Wang Chun You3
Citation :Hu Bo,Cheng Xin Sheng,Wang Chun You, The Experimental Research of BTJF Medicated Serum Inhibiting on Growth of BXPC-3 Pancreatic Cancer Cell International Journal of Clinical Chemistry and Laboratory Medicine 2018, 4(1) : 1-5
Objective: To observe the effect of BUQI TONLUO JIEDU FANG (BTJF) medicated serum inhibiting on growth of BXPC-3 pancreatic cancer cell.
Methods: BTJF drug-containing serum and control group serum cultivate people BXPC3 pancreatic cancer cell in vitro respectively. By MTT method to, detect OD value of pancreatic cancer cells and the cell proliferation rate in each period, use flow cytometry instrument to detect serum the cell number of G0/G1, S,
G2/M phase.
Results: Culture to 4h, the cell survival rate was 93.5%, P > 0.05, there was no significant difference in both groups;24h, the cell survival rate was 71.2%, P < 0.05, the OD value in both groups have significant difference;48h, the cell survival rate was 46.9%, P < 0.05, the OD value in both groups have significant difference;72 h, the cell proliferation rate was 19.7%, P < 0.01, the OD value was extremely significant difference in both groups. In S phase, The percentage in drug-containing serum group significantly lower than the blank control group, P < 0.05, the two groups have significant difference, blank control group in G0/G1 phase cell percentage increased significantly, P < 0.05, two groups have significant difference in statistics.G2/M phase, compared two groups, P > 0.05, no significant difference, the PI value in drugcontaining
serum group was obviously lower than the control group, P < 0.05, there is significant difference
in both group.
Conclusion: BTJF medicated serum have significant effect of inhibiting the proliferation of human pancreatic cancer cell.